<DOC>
	<DOCNO>NCT00977782</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetics AML high risk MDS patient either wild type mutate FLT3 use PKC412 intra-patient dose escalation .</brief_summary>
	<brief_title>Open-label Multicenter Study PKC412 Pts With AML MDS With Either Wild-type Mutated FLT3</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Patients AML candidate myelosuppressive chemotherapy AML relapse disease refractory standard therapy likely require cytoreductive therapy within one month , MDS subtypes RAEB , RAEBT CMML Patients wild type mutate FLT3 document within 14 day prior start study previously receive FLT3 inhibitor . Patients WHO performance status 0 2 life expectancy least 3 month Patients prior allergenic , syngeneic , autologous bone marrow transplant stem cell transplant le 2 month previously . Female patient pregnant breast feed adult childbearing age employ effective method birth control Concurrent severe and/or uncontrolled medical psychiatric condition may interfere completion study Impairment GI function GI disease may significant alter absorption PKC412 Patients 2 prior regimen current relapse current primary refractory disease . Uncontrolled active infection Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>FLT3</keyword>
	<keyword>midostaurin</keyword>
	<keyword>wild type FLT3</keyword>
	<keyword>mutate FLT3</keyword>
</DOC>